| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer
|
Chen K.-H.;Yu-Yun Shao;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Yeh K.-H.;Cheng A.-L.;Lai M.-S.; Chen K.-H.; YU-YUN SHAO; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Young patients with colorectal cancer have increased risk of second primary cancers
|
Liang Y.-H.;Yu-Yun Shao;Chen H.-M.;Lai C.-L.;Lin Z.-Z.;Kuo R.N.;Cheng A.-L.;Yeh K.-H.;Lai M.-S.; Liang Y.-H.; YU-YUN SHAO; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:43Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Lin C.-C.; Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Chen K.-Y.; Liao W.-Y.; Ho C.-C.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-03-24T09:07:53Z |
Sunitinib-induced myxedema coma
|
Shey-Ying Chen;Kao P.-C.;Lin Z.-Z.;Chiang W.-C.;Fang C.-C.; SHEY-YING CHEN; Kao P.-C.; Lin Z.-Z.; Chiang W.-C.; Fang C.-C. |
| 臺大學術典藏 |
2020-03-24T07:38:04Z |
Sunitinib-induced myxedema coma
|
CHENG-CHUNG FANG; Chiang W.-C.; Lin Z.-Z.; Kao P.-C.; Chen S.-Y.; Chen S.-Y.;Kao P.-C.;Lin Z.-Z.;Chiang W.-C.;Cheng-Chung Fang |
| 臺大學術典藏 |
2020-03-06T08:25:25Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; YUNG-MING JENG; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T08:25:24Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Cheng A.-L.; Chung Y.; YUNG-MING JENG; Hu F.-C.; Hsu C.; Kuo S.-H.; Chen T.-J.; Huang Y.-F.; Huang C.-Y.F.; Yeh P.-Y.; Hsu C.-H.; Hsu H.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-03-06T08:25:06Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.;Chang C.-J.;Yung-Ming Jeng;Lin Y.-J.;Lin Z.-Z.;Gandhi A.K.;Liao S.-C.;Huang Z.-M.;Hsu C.;Cheng A.-L.; Ou D.-L.; Chang C.-J.; YUNG-MING JENG; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T08:24:47Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Hsu C.;Yung-Ming Jeng;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Hsu C.; YUNG-MING JENG; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-20T06:53:16Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Liang P.-C.; YU-WEN TIEN |
| 臺大學術典藏 |
2020-02-11T07:58:41Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.;Liang P.-C.;Yao-Ming Wu;Huang C.-C.;Huang K.-W.;Cheng J.C.;Hsu C.-H.;Hsu C.;Cheng A.-L.;Lin Z.-Z.; Shao Y.-Y.; Liang P.-C.; YAO-MING WU; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-02-11T07:58:28Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Hsu C.;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Yao-Ming Wu;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; YAO-MING WU; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-07T01:18:22Z |
Sunitinib-induced myxedema coma
|
Fang C.-C.;WEN-CHU CHIANG;Lin Z.-Z.;Kao P.-C.;Chen S.-Y.; Chen S.-Y.; Kao P.-C.; Lin Z.-Z.; WEN-CHU CHIANG; Fang C.-C. |
| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-01-13T08:25:29Z |
A study of the tool change timing in turning micro V-grooves roller
|
Liao, Y.-S.; Lin, Z.-Z.; Hung, Y.-A.; YUNN-SHIUAN LIAO |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2019 |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; CHIUN HSU; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 國立成功大學 |
2019 |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin, S.;Chan, S.L.;Sukeepaisarnjaroen, W.;Han, G.;Choo, S.P.;Sriuranpong, V.;Pan, H.;Yau, T.;Guo, Y.;Chen, M.;Ren, Z.;Xu, J.;Yen, C.-J.;Lin, Z.-Z.;Manenti, L.;Gu, Y.;Sun, Y.;Tiedt, R.;Hao, L.;Song, W.;Tanwandee, Tanwandee T. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 臺大學術典藏 |
2018-09-10T18:05:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y.-Y.;Chen, B.-B.;Ou, D.-L.;Lin, Z.-Z.;Hsu, C.-H.;Wang, M.-J.;Cheng, A.-L.;Hsu, C.; BANG-BIN CHEN; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T07:20:08Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang, C.-L.;Yang, C.-H.;Yeh, K.-H.;Hu, F.-C.;Chen, K.-Y.;Shih, J.-Y.;Lin, Z.-Z.;Yu, C.-J.;Cheng, A.-L.;Yang, P.-C.; Chong-Jen Yu; KUN-HUEI YEH; JIN-YUAN SHIH; ANN-LII CHENG |
| 國立臺灣科技大學 |
2017 |
Reweighting forest for extreme multi-label classification
|
Lin, Z.-Z.;Dai, B.-R. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 臺大學術典藏 |
2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Bang-Bin Chen;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; Shao Y.-Y.; BANG-BIN CHEN; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
